Introduction Designing a Comparative PK Similarity Study for Biosimilars requires the strategic integration of sensitive population selection, rigorous bioequivalence metrics, […]
Introduction The adoption of the EMA Reflection Paper on a Tailored Clinical Approach introduces a modern regulatory strategy designed to
Introduction Health Canada’s 2026 Biosimilar Guidance establishes a modernized regulatory framework that formally removes the routine requirement for comparative Phase
Introduction Understanding the peptide characterization timeline is essential for pharmaceutical companies preparing an Investigational New Drug (IND) application or an
How Long Does Peptide Characterization Take for an ANDA or IND Submission? Read More »
Introduction Evaluating a peptide purity testing report requires a systematic review of analytical parameters to distinguish raw chromatographic purity from
Introduction: Synthetic Peptide Impurity Analysis is the process of detecting, characterizing and controlling structurally similar impurities that remain after peptide
Introduction Rescuing a delayed Phase I program depends on replacing fragmented, multi-vendor outsourcing arrangements with a single, integrated Contract Development
Introduction: Choosing the right GMP Extractables and Leachables Testing partner is a critical decision for contract development and manufacturing organizations
How CDMOs Should Vet a GMP Extractables and Leachables Testing Partner Read More »
Introduction An ICH Q3D Elemental Impurity Assessment provides a systematic, science-based safety framework for identifying, quantifying, and controlling toxic elemental
Introduction Building an IND-Enabling CMC Analytical Package for a virtual biotech requires establishing a phase-appropriate, regulatory-compliant analytical data package that
Case Study: Building an IND-Enabling CMC Analytical Package for a Virtual Biotech Read More »
